David M. Weber
Net Worth
Last updated:
What is David M. Weber net worth?
The estimated net worth of Dr. David M. Weber is at least $141,964,251 as of 31 Mar 2022. He owns shares worth $44,317,960 as insider, has earned $85,576,611 from insider trading and has received compensation worth at least $12,069,680 in Abiomed, Inc. and Abiomed, Inc..
What is the salary of David M. Weber?
Dr. David M. Weber salary is $754,480 per year as Senior Vice President & Chief Operating Officer in Abiomed, Inc.. He also receives $752,480 as Senior Vice President & Chief Operating Officer in Abiomed, Inc..
How old is David M. Weber?
Dr. David M. Weber is 64 years old, born in 1961.
What stocks does David M. Weber currently own?
As insider, Dr. David M. Weber owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Abiomed, Inc. (ABMD) | Senior Vice President & Chief Operating Officer | 116,314 | $381.02 | $44,317,960 |
What does Abiomed, Inc. do?
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
David M. Weber insider trading
Abiomed, Inc.
Dr. David M. Weber has made 54 insider trades between 2010-2022, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of ABMD stock worth $2,550,000 on 31 Mar 2022.
The largest trade he's ever made was exercising 52,000 units of ABMD stock on 5 May 2016. As of 31 Mar 2022 he still owns at least 116,314 units of ABMD stock.
Abiomed key executives
Abiomed, Inc. executives and other stock owners filed with the SEC:
- Dr. David M. Weber (64) Senior Vice President & Chief Operating Officer
- Mr. Andrew J. Greenfield (52) Vice President & Chief Commercial Officer
- Mr. Marc A. Began (58) Vice President, Gen. Counsel & Sec.
- Mr. Michael R. Minogue (58) Chairman, Chief Executive Officer & Pres
- Mr. Todd A. Trapp (54) Chief Financial Officer & Vice President